Up Close and Personal with Dr. David Nguyen, MD, MBA
Dr.
Ocular Toxicology ― Keeping an EYE on Success
We Share Your Vision
Altasciences has performed safety assessments of test articles administered via numerous ocular routes for over 50 years, including for nanoparticles and ocular implants.
Common routes of administration include, but are not limited to:
- Intravitreal injection
- Subretinal injection
- Anterior chamber injection
- Subconjunctival injection
- Topical instillation
We have supported a significant number of successful global regulatory submissions in terms of study design, conduct, and data integrity. Study durations have ranged from single-dose acute studies to six- and nine-month studies.
You may also be interested in the following:
- Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Flow Cytometry Solutions to Support Your Preclinical and Clinical Studies
Altasciences’ offers scalable flow cytometry solutions, and leverages extensive knowledge to help ensure a smooth transition from preclinical to clinical studies. We provide you with:
- Dedicated flow cytometry scientists available to you early in the process to help determine the most appropriate strategy for non-GLP, GLP, and GCP testing
- Extensive knowledge with exploratory and GLP studies from panel development to validation
- Design and development of receptor occupancy (RO) assays
- Strategically located laboratories in both the U.S. and Canada.
- State-of-the-art instrumentation
- Rapid turnaround between sample collection and analysis
Altasciences has the same instrumentation in its U.S. preclinical site and Canadian site, which allows assay transfer for easy transition from preclinical to clinical studies.
Download flow cytometry fact sheet
Speak to a flow scientist for guidance on your assay development or validation strategy.
You may also be interested in the following:
- Webpage: Therapeutic Areas of Clinical Research
- Fact Sheet: First-in-Human Trials Capabilities
- The Altascientist: Facing Bioanalytical Challenges
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Liquid-Filled Capsules — an Attractive, Marketable Solution
A Scalable Solution for Solubility Challenges
Poorly soluble molecules comprise more than 70% to 80%1 of the small molecule products entering the
Altasciences’ Ethnobridging Solutions Safely Accelerate Drug Development
Clinical data generated by ethnobridging trials in Asian populations are meant to safely accelerate development timelines by evaluating:
- Efficacy
- Safety
- Dosage
- Dosing regimen
In Asia-Pacific countries, ethnobridging studies can reduce drug development timelines by four or five years ― the time it typically takes to complete clinical development in the region versus in North America or Europe.
Discover how you can reduce your drug development timelines.
You may also be interested in the following:
- Blog: Protocol Design Concepts in Phase I Ethnobridging Clinical Trials
- Fact Sheets:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Your CDMO Partner, from Discovery to Commercialization
Whether for a single study or a full drug development program, Altasciences can support you. We offer contract manufacturing and analytical services, including formulation development, Phase I through commercial manufacturing, and ICH stability testing.
Our integrated and synchronized approach to CRO and CDMO services, all under one organizational structure, can save you 25% to 40% in drug development time.
Watch our Executive Vice President of Operations, Ben Reed, discuss our expertise in more detail.
Questions? Speak with an expert!
You may also be interested in the following: